All Paths Lead to Cure
By providing essential lentiviral vector capabilities, we remove barriers and foster innovators to translate groundbreaking science into accessible treatments worldwide.
The future of lentiviral vector innovation and access.
As a public benefit corporation, we’re focused on reaching patients who need it most.
Global Reach
Technologies and processes that make advanced therapies more accessible and affordable, especially in lower-resource settings and underserved regions.
Mobilized Innovation
Modular systems and pre-validated solutions that reduce costs, accelerate timelines, and avoid royalty-based constraints - built to scale anywhere
Value-Driven Partnerships
Systems that are designed to bring proven and streamlined execution of advanced therapy manufacturing without locking therapy manufacturers into costly royalty-based platforms.
Metrics That Matter
We help our partners turn their vision for future therapies into product realities using world-class experience to develop highly optimized Lentiviral vector-based medicines.
We differentiate ourselves by providing our partners algorithm-optimized Lentiviral vectors that are produced using a serum-free, chemically-defined process in the shortest possible turn-around-time. Our manufacturing platform produces high-titer (>10ā¹ TU/ML) Lentiviral vectors for clinical application and commercialization.
Rapid Translation from Concept to Clinic
Vector BioMed provides rapid access to high-titer Lentiviral vectors for partners that need to move quickly to clinical trials and commercialization.
Testimonial
These (vectors) are all EXCELLENT, by the way. Appears the production process is trending upward as these are the highest titers to date.”
Featured Resources
News and Press
Connect with Our Team of Experts
Whether you’re exploring a new gene therapy or need a trusted partner for lentiviral vector design and manufacturing, we’re here to help. Contact us today to discuss your project and learn how Vector BioMed can support your path from concept to clinic.